ArticleEuropean journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology2026
MUREAPLEXE: A multiplex recombinant antigen-based ELISA expanding the serological detection spectrum of urogenital mycoplasmas.
Article in European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThis study aimed to improve the serological identification of urogenital mycoplasmas through the development of MUREAPLEXE, a recombinant protein-based multiplex ELISA allowing the simultaneous and specific detection of antibodies against Metamycoplasma hominis, Ureaplasma parvum and Ureaplasma urealyticum.
methodsGenes encoding the major surface antigens Vaa and P120' of M. hominis, MBA3 of U. parvum and MBA8 of U. urealyticum were cloned into the prokaryotic expression vector pGEX-4T-1 and expressed in E. coli BL21. Recombinant GST-fusion proteins were purified by affinity chromatography using Glutathione-Sepharose 4B beads and were used to optimize an indirect multiplex ELISA. Both assays were subsequently evaluated using 162 patient sera that had been previously characterized by indirect immunofluorescence (IIF) and Western blot analysis.
resultsRelative to IIF, both ELISA assays demonstrated high sensitivity. All tested sera showed reactivity with their corresponding recombinant antigens. Statistical analyses demonstrated a significant correlation between the two ELISA tests. However, MUREAPLEXE demonstrated markedly higher specificity.
conclusionGiven its high sensitivity and specificity for the simultaneous serological identification of M. hominis, U. parvum, and U. urealyticum, MUREAPLEXE may provide a robust and reliable complementary tool for the monitoring of urogenital mycoplasmas.
Indexed as
Identifiers
42412360What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.